Efficacy of Peripheral Magnetic Stimulation versus Sham Control for reducing pain and enhancing motor functions of Upper Trapezius in Myofascial Pain Syndrome : A Double-Blind Randomized Trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260123005

Enrollment

Registered

2026-01-23

Start date

2025-07-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myofascial Pain Syndrome (MPS) in the Upper Trapezius muscle of the neck and shoulder region Myofascial Pain Syndrome Trigger point Upper Trapezius Repetitive Peripheral Magnetic Stimulation Pain Pressure Threshold Visual Analog Scale Muscle strength Neck Disability Index Cervical Range of Motion

Interventions

Peripheral magnetic stimulation works by delivering magnetic pulses to stimulate nerves and muscles in the upper trapezius region where trigger points cause chronic pain. The treatment involves two ph

Sham Comparator Device

Repetitive Pheripheral Magnetic Stimulation

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Symptom Duration: Chronic neck pain more than 3 months interfering with work or daily activities 2. Confirmed myofascial pain syndrome with upper trapezius involvement 3. Moderate pain (VAS score 4-6) 4. Voluntary written consent

Exclusion criteria

Exclusion criteria: 1. Physical modalities used within past 3 months, or other concurrent therapy such as manual therapy, dry needling, massage, other physical therapy 2. Previous magnetic stimulation device use on any time 3. Cervical radiculopathy, musculoskeletal injury, scoliosis, myelopathy, fibromyalgia, migraine, postmenopausal syndrome 4. Autoimmune disorders, malignancy, rheumatoid arthritis 5. Metabolic Diseases such as Diabetes, thyroid disorders, low serum vitamin D levels 6. Contraindications of rPMS : Pregnancy, untreated cancer, epilepsy, pacemaker, cochlear implant, metal implants in skull/spine 7. Severe communication or cognitive problems 8. Recent use of NSAIDs or opioids within past 2 weeks

Design outcomes

Primary

Measure	Time frame
Pain Pressure Threshold before treatment, 2wk, 4wk, 6wk and after treatment ends at 1 mo. kg/s, Algometry	—

Secondary

Measure	Time frame
Visual analog scale before treatment, 2wk, 4wk, 6wk and after treatment ends at 1 mo. mm.,Upper Trapezius muscle strength before treatment, 2wk, 4wk, 6wk and after treatment ends at 1 mo. Dynamometer,Cervical range of motion before treatment, 2wk, 4wk, 6wk and after treatment ends at 1 mo. Goniometer,NDI-TH before treatment, 2wk, 4wk, 6wk and after treatment ends at 1 mo. points	—

Countries

Thailand

Contacts

Public ContactPanyanat Namwong

Faculty of Medicine, Chulalongkorn Hospital

panyanat@docchula.com0820759990

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026